Cryoport, Inc. (OTCBB: CYRX), the leading provider of advanced cryogenic logistics solution, is pleased to announce that Mark Sawicki, Ph.D., chief commercial officer, will speak alongside Robin Hooker, healthcare marketing director for UPS, at the CAR-T Summit in Boston at 3:30 p.m. Nov. 13, 2015.

The two industry leaders will present “Cryo Chain Strategies: From Research to Commercialization” at the Hyatt Regency Cambridge, offering insight into the shipment of cryopreserved biomaterials, cold chain planning, and logistical and risk mitigation strategies used by industry leaders.

“We’re determined to minimize interventions and maximize the quality, timeliness, compliance and overall efficiency of distributing frozen biomaterials globally,” said Sawicki. “We’ll be presenting innovative methods used to monitor and ship biomaterials in all stages of drug development.”

Sawicki has more than 15 years of business development and sales management experience. Prior to joining Cryoport, he held senior management roles at several global pharmaceutical companies.

Hooker helped develop and execute UPS’s health care marketing strategy to serve the unique logistical needs of the health care sector and leverage UPS’s logistics expertise while maintaining regulatory compliance.

The CAR-T Summit, Nov. 12–13, is dedicated to delivering the next generation of safe, effective and commercially viable CAR-T cell therapies. To learn more Cryoport’s cryogenic logistics expertise as well as Cryoport Express®, Cryoportal™ and other innovate offerings, visit Cryoport at Booth 11.

About Cryoport Inc.
Cryoport is the leading provider of cryogenic logistics solutions for temperature-sensitive life sciences materials. With proprietary Cryoport Express® liquid nitrogen dry vapor shippers and packaging, innovative Cryoportal™ technology and cold chain logistics expertise, Cryoport is the preferred cryogenic logistics partner for the world’s largest shipping companies. Visit www.cryoport.com.

Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.